DDX53 and neoplasm: To confirm the novel capacity of ACAT1 in antitumor immunity, we knocked out endogenous Acat1 in CT26 (MSS-CRC) cells and restored Acat1 expression with Acat1-Flag (Supplementary Fig. 1d, e) to examine tumor growth in BALB/c mice and NOD-scid IL2Rgnull (NSG) mice.